STSA-1005 injection

DRUG2 trials

Sponsors

Staidson Biopharma Inc., Staidson (Beijing) Biopharmaceuticals Co., Ltd

Conditions

HealthyHealthy Subject

Phase 1

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

CompletedNCT05085197

Staidson Biopharma Inc.Healthy

Start: 2021-10-27End: 2022-04-05Updated: 2022-04-18

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

TerminatedNCT05559125

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy Subject

Start: 2022-11-08End: 2024-03-26Updated: 2024-05-22